{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:10:48Z","timestamp":1791094248716,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1023\/a:1010684903199","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T03:31:49Z","timestamp":1040614309000},"page":"73-81","source":"Crossref","is-referenced-by-count":88,"title":["Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for \u2018well-tolerated\u2019 treatments?"],"prefix":"10.1007","volume":"66","author":[{"given":"Deborah","family":"Fellowes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christobel M","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"323463_CR1","doi-asserted-by":"crossref","unstructured":"Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1(8319): 257-261, 1983","DOI":"10.1016\/S0140-6736(83)91683-5"},{"issue":"Supp4","key":"323463_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/bjc.1998.754","volume":"78","author":"W Jonat","year":"1998","unstructured":"Jonat W: Luteinizing hormone-releasing hormone analogues-the rationale for adjuvant use in premenopausal women with early breast cancer. Br J Cancer 78(Supp 4): 5-8, 1998","journal-title":"Br J Cancer"},{"key":"323463_CR3","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.1991.00400090120021","volume":"151","author":"RR Love","year":"1991","unstructured":"Love RR, Cameron L, Connell BL, Leventhal H: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151: 1842-1847, 1991","journal-title":"Arch Intern Med"},{"issue":"8","key":"323463_CR4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0277-5379(85)90104-X","volume":"21","author":"G Ribeiro","year":"1985","unstructured":"Ribeiro G, Swindell R: The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma-7-yr results. Eur J Cancer Clin Oncol 21(8): 897-900, 1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"323463_CR5","first-page":"1226","volume":"32","author":"M Baum","year":"1989","unstructured":"Baum M, Houghton J, Riley DL, Melhuish PB: Cancer Research Campaign Adjuvant Breast Trial for Patients Under 50. Horm Res 32 Suppl: 1226-1229, 1989","journal-title":"Horm Res"},{"issue":"4","key":"323463_CR6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0277-5379(89)90200-9","volume":"25","author":"KJ Walker","year":"1989","unstructured":"Walker KJ, Walker RF, Turkes A, Robertson JF, Blamey RW, Griffiths K, Nicholson RI: Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol 25(4): 651-654, 1989","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"1","key":"323463_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00001813-199202000-00001","volume":"3","author":"C Brambilla","year":"1992","unstructured":"Brambilla C, Escobedo A, Artioli R, Lechuga MJ, Motta M: Treatment of pre-menopausal advanced breast cancer with goserelin-a long-acting luteinizing hormone releasing hormone agonist. Anticancer Drugs 3(1): 3-8, 1992","journal-title":"Anticancer Drugs"},{"issue":"45","key":"323463_CR8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/0959-8049(92)90120-Q","volume":"28A","author":"RW Blamey","year":"1992","unstructured":"Blamey RW, Jonat W, Kaufmann M, Bianco AR, Namer M: Goserel in depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 28A(45): 810-814, 1992","journal-title":"Eur J Cancer"},{"issue":"5","key":"323463_CR9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/bjc.1990.397","volume":"62","author":"AR Dixon","year":"1990","unstructured":"Dixon AR, Robertson JF, Jackson L, Nicholson RI, Walker KJ, Blamey RW: Goserel in (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br J Cancer 62(5): 868-870, 1990","journal-title":"Br J Cancer"},{"key":"323463_CR10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998","journal-title":"Lancet"},{"issue":"8419","key":"323463_CR11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0140-6736(85)90966-3","volume":"1","author":"C Rose","year":"1985","unstructured":"Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1(8419): 16-19, 1985","journal-title":"Lancet"},{"key":"323463_CR12","unstructured":"Davidson N, O'Neill A, Vukov A, Osborne CK, Martino S, White D, Abeloff MD: Effect of Chemohormonal Therapy in Premenopausal, Node (C) Receptor (C) Breast Cancer: An Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proc Am Soc Clin Oncol 18Abstract 249, 1999"},{"issue":"9218","key":"323463_CR13","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(00)02292-3","volume":"355","author":"S Aebi","year":"2000","unstructured":"Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A: Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355(9218): 1869-1874, 2000","journal-title":"Lancet"},{"issue":"8","key":"323463_CR14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/oxfordjournals.humrep.a138723","volume":"9","author":"A Shulman","year":"1994","unstructured":"Shulman A, Cohen I, Altaras MM, Maymon R, Ben Nun I, Tepper R, Beyth Y: Ovarian cyst formation in two premenopausal patients treated with tamoxifen for breast cancer. Hum Reprod 9(8): 1427-1429, 1994","journal-title":"Hum Reprod"},{"issue":"1","key":"323463_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0020-7292(94)90767-6","volume":"45","author":"MA Morgan","year":"1994","unstructured":"Morgan MA, Gincherman Y, Mikuta JJ: Endometriosis and tamoxifen therapy. Int J Gynaecol Obstet 45(1): 55-57, 1994","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"323463_CR16","first-page":"154","volume":"15","author":"H Goodare","year":"1999","unstructured":"Goodare H: Breast cancer, tamoxifen, and music therapy. Adv Mind Body Med 15(2): 154-155, 1999","journal-title":"Adv Mind Body Med"},{"key":"323463_CR17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1006263818115","volume":"55","author":"LJ Fallowfield","year":"1999","unstructured":"Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D: Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptoms subscale for the FACT-B. Breast Cancer Res Treat 55: 189-199, 1999","journal-title":"Breast Cancer Res Treat"},{"key":"323463_CR18","doi-asserted-by":"crossref","unstructured":"Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer: Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1(8433): 836-840, 1985","DOI":"10.1016\/S0140-6736(85)92206-8"},{"key":"323463_CR19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0960-9776(96)90021-1","volume":"5","author":"RCF Leonard","year":"1996","unstructured":"Leonard RCF, Lee L, Harrison ME: Impact of side-effects associated with endocrine treatments for advanced breast cancer: clinicians and patients\u2019 perceptions. The Breast 5: 259-264, 1996","journal-title":"The Breast"},{"key":"323463_CR20","doi-asserted-by":"crossref","unstructured":"Hopwood P: Living with advanced breast cancer: development and application of a clinical checklist for patients on endocrine therapy. The Breast 714-721, 1998","DOI":"10.1016\/S0960-9776(98)90046-7"},{"issue":"6supp","key":"323463_CR21","first-page":"50","volume":"8","author":"D Fellowes","year":"1999","unstructured":"Fellowes D, Saunders C, Fallowfield L, Houghton J: Do patients regard hormone therapy received in early breast cancer as worthwhile? (abstract). Psychooncology 8(6 (supp)): 50, 1999","journal-title":"Psychooncology"},{"key":"323463_CR22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/978-3-642-45769-2_38","volume":"152","author":"PA Ganz","year":"1998","unstructured":"Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA: Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152: 396-411, 1998","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"323463_CR23","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO.1999.17.5.1488","volume":"17","author":"JE Mortimer","year":"1999","unstructured":"Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland RH: Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 17(5): 1488-1492, 1999","journal-title":"J Clin Oncol"},{"issue":"4Suppl6","key":"323463_CR24","first-page":"61","volume":"12","author":"JC Allegra","year":"1985","unstructured":"Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, Einhorn L, Ettinger D, Greco F A, Greenwald E, Henderson I, Holmes F, Kinzbrunner B, Luedke S, Muss H, Nimeh N, Talley R, Wampler G, Weinrab N, Weisberg J, Wheeler R, Wiernik P: Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol 12(4 Suppl 6): 61-64, 1985","journal-title":"Semin Oncol"},{"issue":"2Suppl1","key":"323463_CR25","first-page":"45","volume":"24","author":"JC Allegra","year":"1987","unstructured":"Allegra JC: Megestrol acetate: a new role in the treatment of metastatic breast cancer. Semin Hematol 24(2 Suppl 1): 45-47, 1987","journal-title":"Semin Hematol"},{"issue":"11","key":"323463_CR26","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/0959-8049(96)00191-8","volume":"32a","author":"NS Stuart","year":"1996","unstructured":"Stuart NS, Warwick J, Blackledge GR, Spooner D, Keen C, Taylor AR, Tyrell C, Webster DJ, Earl H: A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 32a(11): 1888-1892, 1996","journal-title":"Eur J Cancer"},{"issue":"8","key":"323463_CR27","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1990.8.8.1310","volume":"8","author":"F Boccardo","year":"1990","unstructured":"Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, Scanni A, Sismondi P, Santi L: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. J Clin Oncol 8(8): 1310-1320, 1990","journal-title":"J Clin Oncol"},{"issue":"21","key":"323463_CR28","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson A H, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21): 1529-1542, 1996","journal-title":"J Natl Cancer Inst"},{"issue":"6Suppl9","key":"323463_CR29","first-page":"52","volume":"17","author":"AH Paterson","year":"1990","unstructured":"Paterson AH, Hanson J, Pritchard KI, Sansregret E, Dahrouge S, McDermot RS, Fine S, White DF, Trudeau M, Stewart DJ, Ungar W: Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 17(6 Suppl 9): 52-62, 1990","journal-title":"Semin Oncol"},{"key":"323463_CR30","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1995.13.11.2737","volume":"13","author":"RJ Couzi","year":"1995","unstructured":"Couzi RJ, Helzlsouer K, Fetting JH: Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen therapy. J Clin Oncol 13: 2737-2744, 1995","journal-title":"J Clin Oncol"},{"issue":"6268","key":"323463_CR31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.286.6368.827","volume":"286","author":"G Ribeiro","year":"1983","unstructured":"Ribeiro G, Palmer MK: Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. BMJ 286(6268): 827-830, 1983","journal-title":"BMJ"},{"issue":"10","key":"323463_CR32","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1002\/1097-0142(19871115)60:10<2376::AID-CNCR2820601005>3.0.CO;2-N","volume":"60","author":"P Kellokumpu Lehtinen","year":"1987","unstructured":"Kellokumpu Lehtinen P, Huovinen R, Johansson R: Hormonal treatment of advanced breast cancer. A randomized trial of tamoxifen versus nandrolone decanoate. Cancer 60(10): 2376-2381, 1987","journal-title":"Cancer"},{"issue":"782","key":"323463_CR33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/pgmj.66.782.1029","volume":"66","author":"PJ McDonald","year":"1990","unstructured":"McDonald PJ, Carpenter R, Royle GT, Taylor I: Poor response of breast cancer to tamoxifen. Postgrad Med J 66(782): 1029-1031, 1990","journal-title":"Postgrad Med J"},{"issue":"8Suppl","key":"323463_CR34","first-page":"3458s","volume":"42","author":"TJ Powles","year":"1982","unstructured":"Powles TJ, Gordon C, Coombes RC: Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone. Cancer Res 42(8 Suppl): 3458s-3460s, 1982","journal-title":"Cancer Res"},{"issue":"2","key":"323463_CR35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1997.375","volume":"76","author":"S Pyrhonen","year":"1997","unstructured":"Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A: Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized doubleblind, the \u2018nordic\u2019 phase III study. Br J Cancer 76(2): 270-277, 1997","journal-title":"Br J Cancer"},{"issue":"3","key":"323463_CR36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.7326\/0003-4819-103-3-324","volume":"103","author":"FJ Cummings","year":"1985","unstructured":"Cummings FJ, Gray R, Davis TE, Tormey DC, Harris JE, Falkson G, Arseneau J: Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo. Ann Intern Med 103(3): 324-329, 1985","journal-title":"Ann Intern Med"},{"issue":"10","key":"323463_CR37","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.1995.13.10.2556","volume":"13","author":"DF Hayes","year":"1995","unstructured":"Hayes DF, Zyl JAV, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Shoenfelder J: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13(10): 2556-2566, 1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"323463_CR38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM198101013040104","volume":"304","author":"JN Ingle","year":"1981","unstructured":"Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304(1): 16-21, 1981","journal-title":"N Engl J Med"},{"issue":"2","key":"323463_CR39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1006185805079","volume":"54","author":"PP Peethambaram","year":"1999","unstructured":"Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL: Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 54(2): 117-122, 1999","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"323463_CR40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<683::AID-CNCR14>3.0.CO;2-X","volume":"77","author":"MV Dhodapkar","year":"1996","unstructured":"Dhodapkar MV, Ingle JN, Cha SS, Mailliard JA, Wieand HS: Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials. Cancer 77(4): 683-690, 1996","journal-title":"Cancer"},{"issue":"8Suppl","key":"323463_CR41","first-page":"3461s","volume":"42","author":"JN Ingle","year":"1982","unstructured":"Ingle JN, Green SJ, Ahmann DL, Edmonson JH, Nichols WC, Frytak S, Rubin J: Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure. Cancer Res 42(8 Suppl): 3461s-3467s, 1982","journal-title":"Cancer Res"},{"issue":"8","key":"323463_CR42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8): 479-484, 1989","journal-title":"N Engl J Med"},{"issue":"6","key":"323463_CR43","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1284::AID-CNCR10>3.0.CO;2-P","volume":"85","author":"JN Ingle","year":"1999","unstructured":"Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN: A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85(6): 1284-1292, 1999","journal-title":"Cancer"},{"issue":"2","key":"323463_CR44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1006221425652","volume":"56","author":"K Sugimachi","year":"1999","unstructured":"Sugimachi K, Maehara Y, Akazawa K, Nomura Y, Eida K, Ogawa M, Konaga E, Tanaka N, Toge T, Dohi K, Noda S, Maeda M, Monden Y: Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer. Breast Cancer Res Treat 56(2): 113-124, 1999","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"323463_CR45","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1200\/JCO.1991.9.7.1283","volume":"9","author":"MC Sunderland","year":"1991","unstructured":"Sunderland MC, Osborne CK: Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9(7): 1283-1297, 1991","journal-title":"J Clin Oncol"},{"issue":"22","key":"323463_CR46","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","volume":"89","author":"B Fisher","year":"1997","unstructured":"Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptorpositive breast cancer. J Natl Cancer Inst 89(22): 1673-1682, 1997","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"323463_CR47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/bjc.1989.19","volume":"59","author":"AL Harris","year":"1989","unstructured":"Harris AL, Carmichael J, Cantwell B M, Dowsett M: Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer. Br J Cancer 59(1): 97-99, 1989","journal-title":"Br J Cancer"},{"issue":"8","key":"323463_CR48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.1993.11.8.1529","volume":"11","author":"T Saphner","year":"1993","unstructured":"Saphner T, Troxel AB, Tormey DC, Neuberg D, Robert NJ, Pandya KJ, Edmonson JH, Rosenbluth RJ, Abeloff MD: Phase II study of goserelin for patients with postmenopausal metastatic breast cancer. J Clin Oncol 11(8): 1529-1535, 1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"323463_CR49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/bjc.1991.131","volume":"63","author":"ED Anderson","year":"1991","unstructured":"Anderson ED, Forrest AP, Hawkins RA, Anderson TJ, Leonard RC, Chetty U: Primary systemic therapy for operable breast cancer. Br J Cancer 63(4): 561-566, 1991","journal-title":"Br J Cancer"},{"key":"323463_CR50","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/bjc.1986.106","volume":"53","author":"MR Williams","year":"1986","unstructured":"Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI: The use of an LH-RH agonist (ICI 1 1863 0, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 629-636, 1986","journal-title":"Br J Cancer"},{"issue":"8","key":"323463_CR51","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO.1989.7.8.1113","volume":"7","author":"M Kaufmann","year":"1989","unstructured":"Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Janicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H: Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol 7(8): 1113-1119, 1989","journal-title":"J Clin Oncol"},{"issue":"3","key":"323463_CR52","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1998.16.3.994","volume":"16","author":"CW Taylor","year":"1998","unstructured":"Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, Robert NJ, Budd GT, Paradelo JC, Natale RB, Bearden JD, Mailliard JA, Osborne CK: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16(3): 994-999, 1998","journal-title":"J Clin Oncol"},{"key":"323463_CR53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0360-3016(85)90195-6","volume":"11","author":"MB Parliament","year":"1985","unstructured":"Parliament MB, Danjoux CE, Clayton T: Is cancer treatment toxicity accurately reported? Int J Radiat Oncol Biol Phys 11: 603-608, 1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"323463_CR54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0022-5371(79)90397-9","volume":"18","author":"MJ Watkins","year":"1979","unstructured":"Watkins MJ, Gardiner JM: An appreciation of generaterecognise theory of recall. J Verbal Learning Verbal Behavior 18: 687-704, 1979","journal-title":"J Verbal Learning Verbal Behavior"},{"issue":"3","key":"323463_CR55","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00665698","volume":"27","author":"CK Cathcart","year":"1993","unstructured":"Cathcart CK, Jones SE, Pumroy CS, Peters GN, Knox SM, Cheek JH: Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 27(3): 277-281, 1993","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1010684903199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1010684903199\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1010684903199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1010684903199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:19:48Z","timestamp":1750479588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1010684903199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["323463"],"URL":"https:\/\/doi.org\/10.1023\/a:1010684903199","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}